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In oesophageal squamous cell carcinoma vascular
endothelial growth factor is associated with p53
mutation, advanced stage and poor prognosis
S Uchida, Y Shimada, G Watanabe, H Tanaka, I Shibagaki, T Miyahara, S Ishigami, S Arii and M Imamura
Department of Surgery & Surgical Basic Science, Graduate School of Medicine (formerly First Department of Surgery), Kyoto University, 54-Syogoin kawara-
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Summary Vascular endothelial growth factor (VEGF) affects malignant tumours by promoting angiogenesis. The tumour-suppressor gene
p53 has been thought to regulate VEGF. We investigated the effect of VEGF on oesophageal carcinoma and the connection between VEGF
and p53. One hundred and nine resected oesophageal squamous cell carcinomas were examined. VEGF expression was analysed by
immunohistochemical staining. Sixty-five tumours (59.6%, 65 out of 109) were classified as VEGF positive. A significant correlation was found
between the VEGF expression and both the depth of invasion (P = 0.0001) and lymph node metastasis (P < 0.0001). With regard to p53, we
compared the expression of VEGF with the mutation of p53, examined using polymerase chain reaction-single-strand conformation
polymorphism (PCR-SSCP) and direct sequencing in tumour samples obtained from 36 patients who we have reported previously. The VEGF
expression was significantly correlated to p53 mutation (P= 0.0291). To evaluate the angiogenesis, microvasculardensity (MVD) was counted,
and endothelial cells were stained immunohistochemically using anti-CD34 monoclonal antibody against 29 cases with invasion limited to the
submucosal layer. The average MVD had a tendency to correlate to VEGF expression (P = 0.1626). The prognoses of patients with VEGF-
positive primary tumours were significantly worse than for those with VEGF-negative primary tumours (P = 0.0077). We have assumed that
VEGF contributes to aggressive characteristics in oesophageal carcinomas and that VEGF expression might be affected by p53 status.
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Oesophageal cancer is one of the most lethal malignant
neoplasmas in intestinal diseases. In oesophageal cancer, the
penetration of the muscularis mucosa by the primary tumour
contributes to an increase in lymphatic metastasis and a worsened
prognosis. This is contrary to the case of gastric or colonic
carcinomas in which, within the submuscularis layer, lymphatic
metastasis is rare and the prognosis is not greatly affected by
the penetration ofthe submuscularis layer.
Carcinoma cells secrete several kinds of cytokines, and their
characteristics are influenced by those cytokines. Vascular
endothelial growth factor (VEGF) is one of the influential
cytokines identified in the media conditioned by bovine pituitary
follicular cells (Ferrara et al, 1989). Four types of human VEGF
have been identified, including VEGF121 (121 amino acids),
VEGF165 (165 amino acids), VEGF189 (189 amino acids) and
VEGF206 (206 amino acids). All four types of VEGF are secreted
in abundance by many kinds of carcinoma cells (Ferrara et al,
1992). Around the carcinoma cells, VEGF is thought to play
important roles by directly stimulating endothelial cells to prolif-
erate and migrate, and by activating several proteinase activities
that degrade surrounding matrix tissues.
Recent literature about VEGF expression in oesophageal carci-
noma describes how VEGF contributes to tumour progression and
affects poor prognoses through angiogenesis in oesophageal
squamous cell carcinoma (Inoue et al, 1997).
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In contrast, mutations ofthe tumour-suppressor genep53 trigger
off tumorigenesis, and interestingly some reports show the possi-
bility that they might be connected with angiogenesis. Mutant
p53 could enhance VEGF expression induced by 12-O-tetra-
decanoylphorbol-13-acetate by activating protein kinase C (Kieser
et al, 1994). Other possibilities are that wild-type p53 represses
VEGF transcription, but p53 mutants don't affect promoter
activity, and that wild-type p53 also represses v-Src-mediated
VEGF up-regulation (Mukhopadhyay et al, 1995). Although the
correlation between VEGF and p53 has been suggested in vitro,
there are few reports showing it in clinical materials or in vivo
(Plate et al, 1994).
Previously, we detected mutations of p53 in 47% of
oesophageal squamous cell carcinoma (Wagata et al, 1993;
Shibagaki et al, 1995) and suggested that p53 plays an important
role in oesophageal carcinogenesis.
In this study, we first investigated the correlation between the
clinicopathological factors of oesophageal carcinoma and the
expression ofVEGF by immunohistocytochemistry. Secondly, we
examined whether VEGF might affect the microvascular increase
in oesophageal carcinoma. Finally, we evaluated whether the
expression of VEGF correlated to the status of p53 genes in
oesophageal carcinoma.
MATERIALS AND METHODS
Clinical materials
Tissues were obtained from oesophageal cancer specimens of 109
patients who underwent oesophagectomies at our institution from
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June 1987 to December 1995. The operation techniques used were
as previously described (Imamura et al, 1987). The age of the
patients ranged from 43 to 84 years; 88 were male, 21 were female
(average age, male 64.1 years old, female 61.2 years old). All 109
resected tumours were microscopically examined to identify histo-
logical type, extent and mode ofcancer invasion, and metastasis to
lymph nodes. Histologically, all ofthe patients had squamous cell
carcinoma. Tumour staging was based on the pTNM pathological
classification system. They included five patients with stage 0, 30
with stage I, seven with stage IIA, 19 with stage IIB, 30 with stage
III and 18 with stage IV (Table 1). Lymph node metastatic lesions
of31 ofthe 109 patients were also investigated by VEGF staining.
To examine the influence of VEGF on neovascularization, we
stained and countedendothelial cells of29 ofthe 109patients whose
depths ofinvasion were the same, i.e. to the submucosal layer.
Specimens were fixed in a 10% formaldehyde solution and
embedded in paraffin. Sections, 4 jim thick, were cut and mounted
on glass slides.
Immunohistochemical staining and evaluation
Immunohistochemical staining was performed using the avidin-
biotin method. Tissue sections were deparaffinized and rehydrated
in water. Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide for 30 min. Sections were rehydrated and washed with
phosphate-buffered saline (PBS) and incubated with 1.5% normal
Table 1 Characteristics of 109 patients (mean age 64 years, range 43-84
years) and correlation between the expression of VEGF and clinical
classification
Result of immunostaining
No. of patients (%)
VEGF VEGF Total P-value
negative positive
Sex (number of patients)
Male 36 53 89
Female 8 12 20 0.9704a
TNM clinical classification
T (primary tumour)
Tis (n=5) 5 (100) 0 (0) 5
Ti (n=39) 24 (61.5) 15 (38.5) 39
T2 (n=24) 5 (20.8) 19 (79.2) 24
T3 (n =29) 8 (27.6) 21 (72.4) 29
T4 (n=12) 2 (16.7) 10 (83.3) 12 0.0001
N (regional lymph nodes)
NO (n = 43) 30 (69.8) 13 (30.2) 43
Ni (n = 66) 14 (21.2) 52 (78.8) 66 < 0.0001
M (distant metastasis)
MO (n = 91) 42 (46.2) 49 (53.8) 91
Ml (n=18) 2(11.1) 16(88.9) 18 0.0073a
Stage
o(n=5) 5(100) 0(0) 5
(n =30) 23 (76.7) 7 (23.3) 30
IIA (n = 7) 2 (28.6) 5 (71.4) 7
IIB (n= 19) 4 (21.1) 15 (78.9) 19
IlIl (n=30) 8 (26.7) 22 (73.3) 30
IV (n= 18) 2 (11.1) 16 (88.9) 18 < 0.0001
a Fisher's exact test. The TNM clinical classification of the oesophagus, fourth
fully revised 1987 edition, is used.
goat serum in PBS for 30 min at room temperature to block non-
specific antibody reaction. Sections were incubated overnight at
4°C with anti-human VEGF polyclonal antibody in PBS
containing 1% bovine serum albumin. Anti-human VEGF poly-
clonal antibody was a kind gift from T Ishiwata of the first
Department ofJoint Disease and Department ofPathology, Nippon
Medical School, Tokyo, Japan (Shiraishi et al, 1995). After six
rinses in PBS, sections were incubated for 40 min at room temper-
ature with biotinylated anti-rabbit immunoglobulin G, followed by
six washes with PBS, and reacted with an avidin-biotin system,
using 0.03% 3,3'-diaminobenzide tetrahydrochloride for about
2 min as chromogen. Sections were counterstained with Mayer's
haematoxylin and defined as positive if the membranes or cyto-
plasm ofmore than 10% ofthe tumourcells were stained. Negative
controls, prepared by substituting normal rabbit serum for the
primary antibody, resulted in no detectable staining.
All slides were analysed by two investigators (SU and IS)
without knowledge ofthe patients' clinical information.
Endothelial cells were stained to examine microvascular density
with a monoclonal antibody (QB-END/10; Novocastra Laboratory,
Newcastle, UK) against the endothelial marker (CD34) (Tanigawa
et al, 1996). Immunohistochemical staining was conducted in the
same way as in VEGF. To evaluate microvessel quantitation, slides
were scanned at low-power magnification (x 40 to x 100) to iden-
tify the areas with the highest number of vessels. In each tumour,
the five areas considered to be ofthe highest density were selected
and counted at x200 power magnification, and the averages were
recorded. Vessels with thickmuscular walls and vessels ofa calibre
largerthan approximately eightred blood cells were excluded from
the count. Single endothelial cells or clusters of endothelial cells,
with or without a lumen, were considered to be individual vessels
(Bosari et al, 1992).
Oesophageal carcinoma cell lines
To investigate whether oesophageal carcinoma cells express
VEGF, we screened 18 oesophageal carcinoma cell lines that had
been established in our laboratory (Shimada et al, 1992) We
examined their mRNA expression using the Northern hybridiza-
tion method.
Preparation of RNA from cell lines
TRIzolTM reagent was purchased from Life Technologies.
Cultured cells were lysed with TRIzolTM reagent and scraped
with passing cell lysate several times through a 22-gauge needle.
The cell lysate was then collected in centrifugation tubes, and the
RNA ofthe cells was extracted according to the product's manual.
DNA probes for Northern blot analysis
The DNA probe for human VEGF165 protein was prepared as
follows: 5 jg of human liver total RNA was reverse transcribed
with random primers, using a commercial kit (First Strand
Synthesis Kit; Pharmacia, Piscataway, NJ, USA). The resulting
complementary DNA (cDNA) mixture was subjected to 30 cycles
(1 min at 94°C, 1 min at 550 and 1 min at 72°C) of polymerase
chain reaction (PCR) amplification using a DNA thermal cycler
(Aster, Japan), Taq DNA polymerase (Toyobo, Japan) and specific
VEGF primers. The following oligonucleotide primers, which
were based on the human VEGF cDNA sequence, were used
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Figure 1 Immunohistochemical staining of oesophageal cancer. Specimens were fixed in 10% formaldehyde and embedded in paraffin. An avidin-biotin
complex immunoperoxidase method was performed to detect VEGF using anti-VEGF polyclonal antibody. Stained VEGF appears as granules in cytoplasm of
carcinoma cells (A, magnification x100; B, magnification x400)
(Tischer et al, 1991): #sense primer, 5'-TTGCTGCTCTACCT-
CCAC-3'; and #antisense primer, 5'-AATGCTFTTCTCCGCTCTG-
3'. Two kinds ofPCR products, one of418 base pairs and the other
of 490 base pairs, encoding VEGF165 and VEGF189, respectively,
were obtained. The PCR product that encoded VEGF165 was cloned
into the EcoRV site of the pBluescript SK(-) plasmid (Marchuk et
al, 1991), and the inset was confirmed by sequencing. The insert
was purified and used as a probe in Northern blot analysis.
Northern blot analysis
Hybond N+ nylon membrane, rapid hybridization buffer and the
Megaprime DNA labelling kit were purchased from Amersham
Lifescience (UK). [kx-32P]dCTP was purchased from ICN
Biomedicals (USA). Ten micrograms of mRNA were electro-
phoresed on a 1.0% agarose gel containing 2.2 M formaldehyde
in 1 x 3-(N-morpholino)propanesulphonic acid (MOPS) buffer
(20 mm MOPS, 5 mM sodium acetate, 1 mM EDTA-2Na) and then
transferred to a Hybond N+ nylon membrane by capillary blotting,
followed by ultraviolet (UV) cross-linkage.
Blotted membranes were prehybridized in rapid hybridization
buffer at 65°C for 30 min. [a-32P]dCTP-labelled human VEGF165
cDNA was prepared using a Megaprime DNA labelling kit.
Sephadex-G column was used to remove the free radioisotope.
Hybridization was performed at 65°C for 2 h and then the
membranes were washed twice for 10 min at room temperature in
2 x standard saline citrate (SSC) (300 mM sodium chloride, 30 mM
sodium citrate) with 0.1% sodium dodecyl sulphate (SDS). Ifback-
ground radioactivity was high, membranes were washed again at
65°C for 20 min in 1 x SSC with 0.1% SDS, and then at 65°C for
15 min in 0.1 x SSC with 0.1% SDS. Membranes were exposed to
Fuji radiographic films at -80°C for appropriate intervals. All tech-
niques were performed according to standard methods described
previously (Sambrook et al, 1989). Expression of mRNA was
quantified using the BAS station system (Fuji photo film, Japan).
Statistical analysis
Results among VEGF, p53 mutation and clinical factors were
analysed using x2 analysis and Fisher's exact test. Microvascular
count was analysed using an unpaired t-test. Survival curves of the
Table 2 The stained VEGF detection between primary tumours and lymph
node metastatic lesions
No. of patients with
lymph node metastatic lesions
Primary tumour VEGF negative VEGF positive P-value
VEGF negative 3 2
VEGF positive 11 15 0.4033a
aFisher's exact test.
patients were calculated using the Kaplan-Meier method and statisti-
cally analysed using the generalized Wilcoxon test. Multivariate
analysis was performed using the Cox proportional hazards model.
RESULTS
VEGF was mainly detected on the cytoplasms or the membranes
of the carcinoma cells (Figure 1). Carcinoma cells seemed to stain
stronger on the marginal region of the cancer nest than in the
tumour centre. Few cancer nests were stained diffusely. Vascular
endothelial cells beside strongly stained cancer nests were also
stained. Cancer cells stained more intensely than smooth muscle.
Overall, 65 (59.6%) tumours were classified as VEGF positive.
Table 1 shows the correlation between VEGF expression and
various factors. The VEGF-positive rate exceeded its negative rate
when the tumours grew deeper than T2 level. the VEGF expres-
sion also correlated to lymph nodal metastasis. To evaluate the
status of VEGF at metastatic lymph nodes, lymph node metastatic
lesions were stained immunochemically with anti-VEGF antibody.
Interestingly, we could not find a relationship between the result of
primary lesions and that of lymph node metastatic lesions (Table
2). Ofthe 109 patients, a small group had distant metastasis. When
distant metastasis was detected, a tendency for a higher proportion
of VEGF-positive than VEGF-negative cases was found. As a
result, the VEGF-positive rate became significantly higher
(P<0.0001) with stage advance.
To evaluate the vascular sprouting, the number of endothelial
cells stained by anti-CD34 monoclonal antibody was counted
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Table 3 The association between VEGF and p53
Result of immunostaining
No. of patients
p53 gene status VEGF negative VEGF positive P-value
Mutant type 3 13
Wild type 11 9 0.0291a
aFisher's exact test. p53 status was investigated by PCR-SSCP and direct
sequencing.
Figure 2 Immunohistochemical staining for endothelial cells in a specimen
of oesophageal carcinoma. Anti-CD34 monoclonal antibody was used to
detect endothelial cells. Endothelial cells are stained as vascular ring or
clusters near the tumour (magnification x200)
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Figure 3 Association between microvessel count and the expression of
VEGF. The small dots show the averages of microvessel count out of five
microscopic 200 x fields. The parallel bar and large dots show standard
deviation and the mean value
(Figure 2). Eleven patients out of 29 immunohistochemically
stained cases were defined as VEGF positive. The average of
microvascular density (MVD) in VEGF-positive patients was
higher than that of VEGF-negative patients, but we could not find
a significant difference between them (P = 0.1626) (Figure 3).
With regards to the 36 patients whom we hadpreviously screened
with p53 mutations using polymerase chain reaction-single-strand
conformation polymorphism (PCR-SSCP) and direct sequencing
(Shibagaki et al, 1995), we identified p53 mutations in 16 (44.4%)
of36 tumours in which we found mutations in exons 4-10. Twenty-
two tumours (61.1%) were classified as VEGF positive. We found
that the number of VEGF-positive tumours in p53-mutant tumours
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Figure 4 The relation between the influence of VEGF and survival rate.
Survival curves of the patients were calculated using the Kaplan-Meier
method. Seven out of 109 patients were non-curative cases, therefore we
excluded these patients in this analysis
was significantly higherthan in the wild-type-p53 tumours (Table 3)
(P = 0.0291).
The survival rates of 102 patients who received curative resec-
tion (RO) were examined. (Fifteen out of 18 stage IV patients did
not have organ metastases, except for cervical lymph nodal metas-
tases, which were resected.) Naturally, the survival rate of VEGF-
positive cases was significantly lower than that ofVEGF-negative
cases, proportional to the clinical classification (P = 0.0077)
(Figure 4). Multivariate analysis using Cox's proportional hazards
model revealed that there was no significant correlation between
the expression ofVEGF and the patients' outcome (Table 4).
In our 18 oesophageal carcinoma cell lines, we found various
degrees of VEGF mRNA expression among all 18 cell lines. The
ratio of VEGF mRNA expression to G3PDH varied from 0.547 to
6.45, but no correlation was found between the expression of
VEGF and p53 mutations (Tanaka et al, 1996). Figure 5 shows
representative results ofthe mRNA ofVEGF.
DISCUSSION
Our data show a drastic increase in the number of patients whose
primary tumours were defined as VEGF positive between T1 and
T2 in the depth of invasion [TNM classification of the oesoph-
agus: tumour invades lamina propria or submucosa, (TI); tumour
invades muscularis propria, (T2)]. The number of cases involving
lymph node metastasis increased when the tumour invaded into
the submucosal layer. These increases may correlate with each
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Table 4 Value of five variables in predicting overall survival of 102 patients
Factors Estimate Risk ratio 95% Confidence interval Chi square P-value
pT 0.765 2.148 1.359-3.491 11.120 0.0009
pN 0.045 1.046 0.264--4.356 0.004 0.9493
Sex 1.437 4.210 1.471-17.794 7.896 0.0050
Age 1.013 1.013 0.975-1.053 0.456 0.4994
VEGF 1.804 1.804 0.750-5.011 1.160 0.1976
28s -
18s -4
4--VEGF
4 G3PDH
+ + + + + + + + +
Figure 5 Northern blot analysis of VEGF expression and p53 status in
representative oesophageal cancer cell lines. G3PDH, control of RNA
loading by hybridization with a G3PDH probe. Mutations of p53 were found in
all these cell lines
other, and suggest that VEGF may influence both the growth ofthe
oesophageal carcinoma in transmural invasion and the lymph node
metastasis by affecting at primary sites.
Invasion into the lymphatics could occur through several routes:
by direct invasion of the tumour front into lymph nodes; by inva-
sion of individual cells extruded from the tumour interstitium into
the surrounding tissue; or by the passage oftumour cells from the
bloodstream into the lymphatics via the lymphatic-haematoge-
nous communications (Liotta et al, 1988). Tumour angiogenesis
induced by VEGF may facilitate this process by increasing tumour
volume and superficial area, thus enhancing tumour cell-
lymphatic contact at the growing margin ofthe tumour. It may also
increase the numbers of lymphatic-haematogenous communica-
tions, allowing more intravascular micrometastasis to enter the
lymphatic spaces (Blood et al, 1990). VEGF is also known as
vascular permeability factor and is thought to activate natural
killer cells into connecting with endothelial cells through adhe-
sional molecules (Melder et al, 1996). Furthermore, VEGF has
been shown to induce urokinase-type plasminogen activator
(uPA), tissue-type PA (tPA) and plasminogen activator inhibitor-I
(PAl-1) in vascular endothelial cells and bovine lymphatic
endothelial cells (Pepper et al, 1991, 1994). VEGF also induces
uPA receptor in vascular endothelial cells (Mandriota et al, 1995).
VEGF might facilitate lymph nodal metastasis by degrading
tumour marginal extracellular matrix through uPA and the uPA
receptor system as well as through matrix metalloproteinases
(MMP), some of which might be activated by plasmin. These
connections may facilitate the extravasation ofthe carcinoma cells
at primary sites and may be one cause of VEGF-positive staining
ofprimary tumours increasing lymph node metastasis. In contrast,
our data showed that the expression ofVEGF at metastatic lymph
nodes did not depend on the expression of VEGF at primary
tumours.
With regard to the regulation against the expression of VEGF,
several factors, such as hypoxia, oestrogen levels and p53 muta-
tion, were reported to induce the expression ofVEGF (Schweiki et
al, 1992; Garrido et al, 1993; Kieser et al, 1994; Mukhopadhyay et
al, 1995). Ourresults show that the mutation ofp53 coexisted with
the expression of VEGF in oesophageal carcinoma patients, but
the detailed mechanisms determining how mutant p53 induces
VEGF expression are not known.
It has been reported that increase ofthe microvessels around the
tumour might worsen the prognosis of oesophageal carcinoma.
(Tanigawa et al, 1997). Inoue et al (1997) reported from their
immunohistochemical study of vessel density using anti-factor
VIII antibody that VEGF might mediate angiogenesis in
oesophageal carcinoma. To investigate whether VEGF really
induces microvessels around the oesophageal tumour, we
examined the microvascular density by staining endothelial cells
immunohistochemically, using anti-CD34 antibody. Anti-CD34
antibody is more specific than anti-factor VIII antibody and,
because the average vessel counts were approximately three times
higher with CD34 staining than with factor VIII staining
(Tanigawa et al, 1997), it may be controversial to evaluate vessel
density using anti-factor VIII antibody. Although we could not
find a significant difference in microvascular density between
VEGF-positive cases and VEGF-negative cases, we found that
the VEGF-positive cases tended to show a higher number of
microvascular counts than VEGF-negative cases. Even if they
were normal tissues, the basic number of the endothelial cells in
each layer varied. In the case ofcarcinoma tissues, the endothelial
cell count at different layers may be influenced by the variety of
the basic number of them. In many cases, the structure of the
muscular layertissues invadedby the carcinoma was destroyed too
severely to investigate endothelial cell numbers, so our research
was limited to 29 cases whose depths of invasion were at the
submucosal layer. We could not show a significant difference
in endothelial cell numbers between VEGF-positive cases and
VEGF-negative cases.
Finally, although there is the possibility that cancer cell lines
may change their natural character, we confirmed VEGF expres-
sion in oesophageal cancer by detecting its mRNA in cell lines.
Our results may indicate that the expression of VEGF is common
in oesophageal cancer and well correlated with p53 status in vivo;
however the same correlation was not shown in vitro. There may
be the involvement ofother factors. We have already examined the
p53 status of these cell lines (Tanaka et al, 1995), so we are now
analysing them for direct evidence of a correlation between p53
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mutation and VEGF expression. These attempts should contribute
to a better understanding ofthe growth mechanisms ofoesophageal
cancer.
ABBREVIATIONS
VEGF, vascular endothelial growth factor; PCR-SSCP, polymerase
chain reaction-single-strand conformation polymorphism; PA,
plasminogen activator; uPA, urokinase-type PA; tPA, tissue-type
PA; MVD, microvascular density; PBS, phosphate-buffered saline
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